Cargando…
Clinical and Economic Impact of Implementing OVIVA Criteria on Patients With Bone and Joint Infections in Outpatient Parenteral Antimicrobial Therapy
The OVIVA study demonstrated noninferiority for managing bone and joint infections (BJIs) with oral antibiotics. We report that 79.7% of OPAT patients being treated for BJIs at our center would be eligible for oral antibiotics, saving a median (IQR) 19.5 IV-antibiotic days (8.5–37) and GBP 1234 (569...
Autores principales: | Marks, Michael, Bell, Lucy C K, Jones, Imogen, Rampling, Tommy, Kranzer, Katharina, Morris-Jones, Stephen, Logan, Sarah, Pollara, Gabriele |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7312207/ https://www.ncbi.nlm.nih.gov/pubmed/31603189 http://dx.doi.org/10.1093/cid/ciz991 |
Ejemplares similares
-
1282. Evaluation of Opportunities for Implementing OVIVA Criteria on Patients with Bone and Joint Infections (BJIs) in Outpatient Parenteral Antimicrobial Therapy (OPAT)
por: Crawford, Garrett, et al.
Publicado: (2023) -
Intravenous catheter-related adverse events exceed drug-related adverse events in outpatient parenteral antimicrobial therapy
por: Underwood, Jonathan, et al.
Publicado: (2019) -
Shortening duration of ertapenem in outpatient parenteral antimicrobial therapy for complicated urinary tract infections: A retrospective study
por: Fink, Doug L., et al.
Publicado: (2019) -
Oral versus intravenous antibiotic treatment for bone and joint infections (OVIVA): study protocol for a randomised controlled trial
por: Li, Ho Kwong, et al.
Publicado: (2015) -
Cost-effectiveness of oral versus intravenous antibiotics (OVIVA) in patients with bone and joint infection: evidence from a non-inferiority trial
por: McMeekin, Nicola, et al.
Publicado: (2020)